EP3607947 - COMBINATION OF TAFIA INHIBITOR WITH PLASMINOGEN ACTIVATOR [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 15.01.2021 Database last updated on 22.08.2024 | |
Former | Request for examination was made Status updated on 10.01.2020 | Most recent event Tooltip | 15.01.2021 | Application deemed to be withdrawn | published on 17.02.2021 [2021/07] | Applicant(s) | For all designated states Daiichi Sankyo Company, Limited 3-5-1, Nihonbashi Honcho Chuo-ku Tokyo 103-8426 / JP | [2020/07] | Inventor(s) | 01 /
NOGUCHI, Kengo c/o Daiichi Sankyo Company, Limited 1-2-58, Hiromachi Shinagawa-ku, Tokyo / JP | 02 /
ITO, Yusuke c/o Daiichi Sankyo Company, Limited 1-2-58, Hiromachi Shinagawa-ku, Tokyo / JP | 03 /
EDO, Naoko c/o Daiichi Sankyo Company, Limited 1-2-58, Hiromachi Shinagawa-ku, Tokyo / JP | [2020/07] | Representative(s) | Nieuwenhuys, William Francis Marks & Clerk LLP 15 Fetter Lane London EC4A 1BW / GB | [2020/07] | Application number, filing date | 19180386.5 | 16.06.2016 | [2020/07] | Priority number, date | JP20150121856 | 17.06.2015 Original published format: JP 2015121856 | [2020/07] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3607947 | Date: | 12.02.2020 | Language: | EN | [2020/07] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 03.01.2020 | Classification | IPC: | A61K31/4172, A61K31/4178, A61K38/48, A61P7/02, A61P43/00, A61K38/49, A61P9/00, A61P39/00 | [2020/07] | CPC: |
A61K31/4172 (EP,KR,US);
A61K31/4178 (EP,KR,US);
A61K38/48 (EP,KR,US);
A61K38/49 (EP,US);
A61P39/00 (EP,US);
A61P7/02 (KR);
A61P9/00 (EP,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/07] | Title | German: | KOMBINATION AUS TAFIA-INHIBITOR UND PLASMINOGENAKTIVATOR | [2020/07] | English: | COMBINATION OF TAFIA INHIBITOR WITH PLASMINOGEN ACTIVATOR | [2020/07] | French: | COMBINAISON D'UN INHIBITEUR DE TAFIA AVEC UN ACTIVATEUR DE PLASMINOGÈNE | [2020/07] | Examination procedure | 14.06.2019 | Examination requested [2020/07] | 13.08.2020 | Application deemed to be withdrawn, date of legal effect [2021/07] | 14.09.2020 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2021/07] | Parent application(s) Tooltip | EP16811713.3 / EP3311812 | Fees paid | Renewal fee | 14.06.2019 | Renewal fee patent year 03 | 14.06.2019 | Renewal fee patent year 04 | Penalty fee | Additional fee for renewal fee | 30.06.2020 | 05   M06   Not yet paid |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XY]EP2548871 (DAIICHI SANKYO CO LTD [JP]) [X] 1-6,8-18 * claims 1,80 * * examples 19,20,22,23,27,32 * * claims 63-69 * * paragraph [0191] * * example 2 * * page 652 * [Y] 7; | [Y] - N. J. MUTCH ET AL, "Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, GB, (20030901), vol. 1, no. 9, doi:10.1046/j.1538-7836.2003.00383.x, ISSN 1538-7933, pages 2000 - 2007, XP055338777 [Y] 7 * summary * * figure 2 * DOI: http://dx.doi.org/10.1046/j.1538-7836.2003.00383.x | by applicant | WO2011115064 | - SUZUKI et al., The Journal of Pharmacology and Experimental Therapeutics, (20040000), vol. 309, pages 607 - 615 | - WANG et al., Thrombosis and Haemostasis, (20070000), pages 54 - 61 |